BR112016001446A8 - composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida - Google Patents
composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainidaInfo
- Publication number
- BR112016001446A8 BR112016001446A8 BR112016001446A BR112016001446A BR112016001446A8 BR 112016001446 A8 BR112016001446 A8 BR 112016001446A8 BR 112016001446 A BR112016001446 A BR 112016001446A BR 112016001446 A BR112016001446 A BR 112016001446A BR 112016001446 A8 BR112016001446 A8 BR 112016001446A8
- Authority
- BR
- Brazil
- Prior art keywords
- flecainide
- combination product
- therapeutic compositions
- vitro use
- anticonnexin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
resumo uso de flecainida como agente anticonexina e método de potencialização dos efeitos de droga psicotrópica a presente invenção refere-se ao uso de flecainida como agente anticonexina. esse agente anticonexina é convenientemente utilizado para potencializar o efeito terapêutico de diversas drogas psicotrópicas. mais especificamente, a presente invenção fornece um produto de combinação que contém flecainida e modafinil.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13306074 | 2013-07-24 | ||
PCT/EP2014/065975 WO2015011246A1 (en) | 2013-07-24 | 2014-07-24 | Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016001446A2 BR112016001446A2 (pt) | 2017-08-29 |
BR112016001446A8 true BR112016001446A8 (pt) | 2018-01-23 |
Family
ID=48900920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016001446A BR112016001446A8 (pt) | 2013-07-24 | 2014-07-24 | composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida |
Country Status (20)
Country | Link |
---|---|
US (3) | US9750734B2 (pt) |
EP (2) | EP3308785A3 (pt) |
JP (3) | JP6192830B2 (pt) |
KR (2) | KR20170068629A (pt) |
CN (1) | CN105579041B (pt) |
AU (1) | AU2014295030B2 (pt) |
BR (1) | BR112016001446A8 (pt) |
CA (2) | CA2919140C (pt) |
DK (1) | DK3024458T3 (pt) |
ES (1) | ES2661647T3 (pt) |
HR (1) | HRP20180487T1 (pt) |
HU (1) | HUE037122T2 (pt) |
IL (2) | IL243746A (pt) |
MX (2) | MX365782B (pt) |
PL (1) | PL3024458T3 (pt) |
PT (1) | PT3024458T (pt) |
RU (2) | RU2018122564A (pt) |
TR (1) | TR201802302T4 (pt) |
WO (1) | WO2015011246A1 (pt) |
ZA (1) | ZA201601146B (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2992162A1 (en) * | 2015-07-15 | 2017-01-19 | Theranexus | Use of amitriptyline for blocking brain hemichannels and method for potentiating its effect in vivo |
US10744087B2 (en) | 2018-03-22 | 2020-08-18 | Incarda Therapeutics, Inc. | Method to slow ventricular rate |
WO2019204326A1 (en) * | 2018-04-16 | 2019-10-24 | Alsar Ltd Partnership | Compositions and methods for sustained release of flecainide |
US20210255198A1 (en) * | 2018-06-11 | 2021-08-19 | The United States of America as Represented by the Department of Veterans Affairs Office | Methods for objective assessment of stress, early detection of risk for stress disorders, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs |
US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
EP3593822A1 (en) | 2018-07-13 | 2020-01-15 | Theranexus | Therapeutic and diagnostic applications of a new method of monitoring of neuroglial interaction memri) |
US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
US11021410B2 (en) * | 2018-12-10 | 2021-06-01 | Purdue Research Foundation | Layer-wise agglomerated urea granules |
US11020384B2 (en) | 2019-08-01 | 2021-06-01 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
WO2021025985A1 (en) * | 2019-08-02 | 2021-02-11 | Praxis Precision Medicines, Inc. | Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression |
CN111018694A (zh) * | 2019-12-12 | 2020-04-17 | 贵州省欣紫鸿药用辅料有限公司 | 一种氟卡尼的生产方法 |
CN116096900A (zh) * | 2020-05-13 | 2023-05-09 | 阿库斯股份有限公司 | 用于治疗gjb2相关听力损失的组合物和方法 |
KR102390194B1 (ko) * | 2020-08-03 | 2022-04-25 | 셀라이온바이오메드 주식회사 | 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물 |
WO2022170081A1 (en) * | 2021-02-05 | 2022-08-11 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001253825A (ja) | 2000-03-13 | 2001-09-18 | Masahiko Ichimada | 帯状疱疹後神経痛用鎮痛剤 |
US7799832B2 (en) * | 2003-10-23 | 2010-09-21 | Valeant Pharmaceuticals North America | Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
KR20080067628A (ko) * | 2005-11-21 | 2008-07-21 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 알라바마 포 앤드 온 비하프 오브 더 유니버시티 오브 알라바마 | 신경보호를 위한 소분자 화합물의 사용 방법 |
JP5960944B2 (ja) * | 2006-11-15 | 2016-08-02 | コーダ セラピューティクス, インコーポレイテッド | 創傷治癒のための改善された方法および組成物 |
FR2935611B1 (fr) * | 2008-09-10 | 2010-10-15 | Commissariat Energie Atomique | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes |
WO2012042541A2 (en) | 2010-09-30 | 2012-04-05 | Council Of Scientific & Industrial Research | Method for predicting and modeling anti-psychotic activity using virtual screening model |
US20130096067A1 (en) | 2011-09-14 | 2013-04-18 | Norbert Perrimon | Drosophila tumor stem cell model and uses thereof |
EP2586436A1 (en) * | 2011-10-31 | 2013-05-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor |
-
2014
- 2014-07-24 JP JP2016528540A patent/JP6192830B2/ja not_active Expired - Fee Related
- 2014-07-24 US US14/907,221 patent/US9750734B2/en active Active
- 2014-07-24 BR BR112016001446A patent/BR112016001446A8/pt not_active Application Discontinuation
- 2014-07-24 TR TR2018/02302T patent/TR201802302T4/tr unknown
- 2014-07-24 WO PCT/EP2014/065975 patent/WO2015011246A1/en active Application Filing
- 2014-07-24 KR KR1020177015674A patent/KR20170068629A/ko not_active IP Right Cessation
- 2014-07-24 DK DK14742249.7T patent/DK3024458T3/en active
- 2014-07-24 AU AU2014295030A patent/AU2014295030B2/en not_active Ceased
- 2014-07-24 MX MX2016001049A patent/MX365782B/es active IP Right Grant
- 2014-07-24 HU HUE14742249A patent/HUE037122T2/hu unknown
- 2014-07-24 RU RU2018122564A patent/RU2018122564A/ru not_active Application Discontinuation
- 2014-07-24 EP EP17203646.9A patent/EP3308785A3/en active Pending
- 2014-07-24 ES ES14742249.7T patent/ES2661647T3/es active Active
- 2014-07-24 PT PT147422497T patent/PT3024458T/pt unknown
- 2014-07-24 PL PL14742249T patent/PL3024458T3/pl unknown
- 2014-07-24 CN CN201480051866.3A patent/CN105579041B/zh active Active
- 2014-07-24 RU RU2016105971A patent/RU2661026C2/ru active
- 2014-07-24 KR KR1020167004739A patent/KR101754045B1/ko active IP Right Grant
- 2014-07-24 CA CA2919140A patent/CA2919140C/en active Active
- 2014-07-24 CA CA2997282A patent/CA2997282A1/en not_active Abandoned
- 2014-07-24 EP EP14742249.7A patent/EP3024458B1/en active Active
-
2016
- 2016-01-21 IL IL243746A patent/IL243746A/en active IP Right Grant
- 2016-01-22 MX MX2019006878A patent/MX2019006878A/es unknown
- 2016-02-19 ZA ZA2016/01146A patent/ZA201601146B/en unknown
-
2017
- 2017-03-27 JP JP2017061022A patent/JP6453931B2/ja not_active Expired - Fee Related
- 2017-08-03 US US15/667,999 patent/US20180028519A1/en not_active Abandoned
- 2017-08-29 IL IL254210A patent/IL254210B/en unknown
-
2018
- 2018-03-26 HR HRP20180487TT patent/HRP20180487T1/hr unknown
- 2018-09-21 US US16/138,641 patent/US10639301B2/en active Active
- 2018-12-13 JP JP2018233114A patent/JP6694497B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016001446A8 (pt) | composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida | |
BR112016020618A8 (pt) | oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido | |
NZ726746A (en) | Stable cannabinoid formulations | |
BR122021018243A8 (pt) | Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável | |
UY35907A (es) | Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmaceuticas que las contienen, así como su uso para la preparación de medicamentos | |
BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
BR112015022545A2 (pt) | compostos de pirazolo e os usos disso | |
BR112018001755A2 (pt) | composições de insulina de ação rápida | |
BR112018010671A8 (pt) | dispositivos e métodos de distribuição de fármaco com mudança de forma | |
DOP2014000059A (es) | Derivados de estra1,3,5(10),16tetraen3carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
PE20150353A1 (es) | Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos | |
BR112013024824A2 (pt) | ésteres isopentílicos para uso em composições cosméticas, dermatológicas ou farmacêuticas | |
BR112014020113A8 (pt) | Composições farmacêuticas e método para diminuir a frequência de micção | |
BR112015027017A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas | |
BR112016013754A2 (pt) | Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma | |
BR112015012920A2 (pt) | gel oral para dor de dente e sensibilidade | |
BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
BR112014015578A8 (pt) | composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide | |
BR112013003064A2 (pt) | agente profilático ou terapêutico para a esteato-hepatite não alcoólica | |
BR112015022117A2 (pt) | precursor da composição cosmética, composição cosmética para a aplicação tópica, método para a administração de um agente cosmético sólido e amida de triciclodecano | |
BR112015015250A2 (pt) | derivados de pirrolidina, composições farmacêuticas e usos dos mesmos | |
BR112014030288A8 (pt) | composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila | |
BR112015030594B8 (pt) | peça dentária manual para a pulverização de pó | |
BR112017022855A2 (pt) | combinação de dose fixa inviolável que provê liberação rápida de dois fármacos a partir de partículas e um pó |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |